Group 1 - The US and China held talks in Madrid on September 14 regarding trade issues, including US unilateral tariff measures and export controls [4] - The Ministry of Industry and Information Technology and seven other departments issued the "Automobile Industry Stabilization Growth Work Plan (2025-2026)" [2][11] - The Shanghai Stock Exchange announced the candidate list for the third Technology Innovation Advisory Committee, including notable entrepreneurs [2][5] Group 2 - The broad money supply (M2) increased by 8.8% year-on-year in August, with non-bank financial institutions' deposits increasing by 550 billion yuan [5] - The National Internet Information Office released a draft for public consultation on promoting and regulating electronic document applications, proposing the exploration of digital RMB for cross-border payments [5] - The film market's box office for 2025 has surpassed 40 billion yuan as of September 13, 2025, 76 days ahead of 2024 [5] Group 3 - The first project of the third phase of the National Integrated Circuit Industry Investment Fund targets semiconductor equipment, with a capital increase of 4.5 billion yuan for Tuojing Technology [10] - Domestic semiconductor equipment has shown strong growth trends, with the market expected to maintain a long-term scale of over 40 billion USD [10] Group 4 - The "Automobile Industry Stabilization Growth Work Plan" aims to promote the industrial application of intelligent connected technology, with a projected industry value increase of 725.9 billion yuan by 2025 [11] - The plan encourages the development of new business models using data and supports the production of L3-level vehicles [11][13] Group 5 - The "New Energy Storage Scale Construction Special Action Plan (2025-2027)" aims for a new energy storage installation scale of over 180 GW by 2027, driving direct investment of about 250 billion yuan [14][15] - Companies like Haibo Technology and Sungrow Power have reported significant revenue growth in their energy storage systems [15] Group 6 - TCL Technology plans to invest approximately 29.5 billion yuan to build an 8.6-generation printed OLED production line [17] - Haizheng Pharmaceutical has received a CEP certificate for its Tigecycline raw materials, marking a significant step for international market expansion [19] - Zhongchao Holdings signed a strategic cooperation agreement with Hefei Intelligent Robot Research Institute to promote applications in intelligent robotics [20]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、CEP证书相关信息 药品名称：TIGECYCLINE/替加环素 本次公司替加环素原料药获得CEP认证证书，显示欧洲规范市场对该原料药质量的认可和肯定，标志此 产品具备以原料药形式进入欧盟及承认CEP证书的其他市场的资质，为公司进一步拓展国际市场带来积 极的影响。 国际原料药业务易受海外市场环境变化、汇率波动等因素影响，敬请广大投资者理性投资，注意投资风 险。 近日，浙江海正药业股份有限公司（以下简称"公司"）收到欧洲药品质量管理局（European Directorate for the Quality of Medicines & HealthCare，以下简称"EDQM"）签发的替加环素原料药欧洲药典适用性 认证证书（Certificate of Suitability to Monograph of European Pharmacopoeia，以下简称"CEP证书"），现 就相关情况公告如下： 产品剂型：原料药 证书编号：No. CEP 2024-176 - Rev ...

替加环素主要适用于18岁以上患者在下列情况下由特定细菌的敏感菌株所致感染的治疗：复杂性腹腔内 感染、复杂性皮肤和皮肤软组织感染、社区获得性细菌性肺炎。 格隆汇9月12日丨海正药业(600267.SH)公布，公司收到欧洲药品质量管理局（European Directorate for the Quality of Medicines & HealthCare，简称"EDQM"）签发的替加环素原料药欧洲药典适用性认证证书 （Certificate ofSuitability to Monograph of European Pharmacopoeia，简称"CEP 证书"）。 ...

Core Viewpoint - Haizheng Pharmaceutical has received the CEP certificate for Tigecycline raw materials from the European Medicines Agency, marking it as the first domestic company to achieve this certification, which enhances its qualifications for entering the EU and other markets that recognize the CEP certificate [1] Group 1 - The receipt of the CEP certificate signifies recognition and affirmation of the quality of the raw material by the European regulatory market [1] - This certification allows the company to expand its international market presence positively [1]

Core Viewpoint - The company has received the CEP certificate for tigecycline active pharmaceutical ingredient from the European Directorate for the Quality of Medicines and HealthCare (EDQM), marking a significant achievement as the first domestic enterprise to obtain this certification [1] Group 1 - The global sales volume of tigecycline active pharmaceutical ingredient is approximately 290.22 kilograms for the period from January to June 2025 [1]